Biologics Debated At House Subcommittee Hearing

Law360, New York (May 2, 2007, 12:00 AM EDT) -- The U.S. Food and Drug Administration should be able to approve some generic or follow-on biologic products if given the ability to do so, an agency official said at a hearing Wednesday.

Dr. Janet Woodcock, the agency’s deputy commissioner and chief medical officer, told a subcommittee of the U.S. House of Representatives Energy and Commerce Committee that the agency had previously approved some similar protein products. She also told the Subcommittee on Health that science will continue to evolve, a fact Congress should consider when writing...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.